AllDocs -> cancers

Epidemiology The incidence of bladder cancer in the United States in the year 2000 was approximately 21 per 100,000 persons. 3 The American Cancer Society estimates that 60,240 new cases of bladder cancer will be diagnosed in the United States during 2004 (about 44,640 men and 15,600 women), and about 12,710 people will die of the disease (about 8,780 men and 3,930 women). 4 Bladder cancer occurs primarily in men older than 60 and roughly twice as frequently in white men as in black men. 3 Men are 2.5 times more likely to be diagnosed with bladder cancer than women; age-adjusted mortality rates from bladder cancer are similarly higher for men than for women. Cigarette smoking is the greatest environmental risk factor for bladder cancer . Cigarette smokers are 4 to 7 times more likely to develop bladder cancer ...

181 Burden of Suffering Bladder cancer is an important cause of morbidity and mortality in the U.S., primarily in older men. Over 50,000 new cases and over 11,000 deaths due to bladder cancer are predicted to occur in 1995 in the U.S. 1 Risk rises steeply with age; over half of all deaths from bladder cancer occur after age 70. The incidence of bladder cancer is 3–4 times higher in men than women, and roughly twice as high in white men compared to black men. 2,3 Among white men, the annual incidence of bladder cancer after age 65 is approximately 2/1,000 persons (vs. 0.1/1,000 under 65), and the lifetime probability of developing cancer is over 3%. 3 The proba- bility of dying from bladder cancer is much smaller, however—less than 1%. Cigarette smoking markedly increases the risk for bladder cancer (rel- ative risk among smokers vs. ...

J Pharm Pharmaceut Sci (www.cspsCanada.org) 8(3):536-543, 2005 536 Distribution of Photosensitizers in Bladder Cancer Spheroids: Implications for Intravesical Instillation of Photosensitizers for Photodynamic Therapy of Bladder Cancer Zhengwen Xiao 1 , Christian B. Hansen 2, 3 , Theresa M. Allen 2 , Gerald G. Miller 4 and Ronald B. Moore 1 Departments of 1 Surgery, 1 Oncology, and 2 Pharmacology, University of Alberta, Edmonton, Alberta, Canada 3 AltaRex Corporation, Edmonton, Alberta, Canada. 4 Noujaim Institute for Pharmaceutical Oncology Research, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada ...

Reference Section a report by Seth Ler ner , MD Associate Professor of Urology, Scott Department of Urology (SDU) and Beth and Dave Swalm Chair, Urologic Oncology, Baylor College of Medicine, Houston Cystoscopy with PDD Offers Promise for Improved Bladder Cancer Detection B U S I N E S S B R I E F I N G : U S K I D N E Y & U RO L O G I C A L D I S E A S E 2 0 0 5 1 Bladder cancer currently accounts for a significant number of malignancies diagnosed each year in the US. Conventional methods for detecting the presence of malignancies in the bladder rely on cystoscopy and urine cytology.While effective, they are limited in their ability to detect early subclinical forms of the disease and dysplastic lesions that appear visibly normal. Progress in the development of photodynamic diagnosis, which combines the capabilities ...

Dr Peter Oehr is Professor of Nuclear Medicine at the University of Bonn, Germany. He is an independent expert for the German Federal Institute for Drugs and Medical Devices (BfArM) and is also the Editor of PET and PET-CT in Oncology (Springer, 2004). He was the private instructor for experimental nuclear medicine from 1988 to 2000 at the University of Bonn. From 1975 to 1979 he worked in the surgical clinic at Bonn University, working on transplantation, immunology and experimental surgery, and was leader of the experimental and clinical laboratories in the clinic of nuclear medicine at the same university. From 1964 to 1970 he studied at the universities of Freiburg, Tübingen and London, gaining a diploma in biology. Dr Oehr has also been a visiting lecturer at the University of Dusseldorf, lecturing in laser medicine, and Associate Professor ...

Arnulf Stenzl is Professor and Chairman at the Department of Urology, Eberhard-Karls-University, Tübingen, Germany. He is a member of numerous societies and organisations, including the European Society of Urologic Oncology and Endocrinology (ESUOE), the American Association of Cancer Research (AACR) and the European Association of Urology (EAU). He is the recipient of numerous awards, including an honourary ‘Professor of Urology’ title awarded by the Federal President of Austria, September 1997. He is a section editor for European Urology , a guest editor for World Journal of Urology, “Urinary Diversion in the New Millennium” and Member of the Executive Board for the British Journal of Urology International . a report by Arnulf Stenzl and Gerhard Feil Department of Urology, University of Tübingen, ...

Incidence and Mortality Rate Trends While urinary bladder cancer incidence is significantly higher in Whites than in African Americans, the mortality rates are nearly the same, due in large part to the later stage at diagnosis among African Americans. Rates for Hispanics, Asians or Pacific Islanders, and AmericanIndians/AlaskanNativesarelowerthan those for Whites or African Americans. Overall incidence has stayed the same or risen slightly since the 1980s, but mortality dropped through the 1980s, resulting in increased survival. Men have greater incidence and mortality rates than women in all ethnic groups. It is estimated that approximately $2.9 billion* is spent in the United States each year on the treatment of bladder cancer . *In 2004 dollars, as reported in Brown ML, Riley GF, Schussler N, and Etzioni RD. Estimating health care costs ...

National Cancer Institute SEER Program 124 URINARY BLADDER T he highest incidence rates for bladder cancer are found in industrialized countries such as the United States, Canada, France, Denmark, Italy, and Spain. Rates are lower in England, Scotland, and Eastern Europe. The lowest rates are in Asia and South America, where the incidence is only about 30% as high as in the United States. In all countries the rates are higher for men than women. In the SEER regions, for the period 1988 to 1992, the incidence rates are generally three to four times higher in men than in women. Among men, the highest rates are in white non-Hispanics (33.1 per 100,000). The rates for black men and Hispanic men are similar and are about one- half the white non-Hispanic rate. The lowest rates are in the Asian populations. For women, the highest ...

Guidelines on bladder cancer Willem Oosterlinck 1 , Bernard Lobel 2 , Gerhard Jakse 3 , Per-Uno Malmström 4 , Michael Stöckle 5 , Cora Sternberg 6 and the EAU working group on Oncological Urology* 1) University Hospital Ghent, Belgium 2) CHRU Pontchaillou Rennes, France 3) University Clinics RWTH Aachen, Germany 4) University Hospital Uppsala, Sweden 5) University Saarland, Homburg/Saar, Germany 6) Clinic Pio XI, Rome, Italy Keywords : bladder cancer , superficial bladder cancer , guidelines Address for correspondence : Prof. Dr.W. Oosterlinck Department of Urology University Hospital Ghent De Pintelaan 185 B-9000 Gent Belgium Tel : 0032 9 240 2276 Fax : 0032 9 240 3889 E-mail : willem.oosterlinck@rug.ac.be ...

A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: • No. of cases: 45 • Tissue type: Urinary bladder cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) •Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 11 A B C D E F G H I : Urothelial carcinoma : Urothelial carcinoma in situ : Adenocarcinoma + other pathology : Squamous carcinoma : Non-neoplastic Page 2 ...

Bladder Cancer Stage IV Stage III Stage II Stage I T1- Tumor invades the subepithelial connective tissue T2- Tumor invades muscle T2a- Tumor invades the superficial muscle T2b- Tumor invades deep muscle T3- Tumor invades perivesical tissue T3a- Microscopically T3b- Macroscopically T4- Tumor invades prostate, uterus, vagina, pelvic wall, or abdominal wall T4a- Tumor invades the prostate, uterus, or vagina T4b- Tumor invades the pelvic wall, abdominal wall N0- No regional lymph node metastasis N1- Metastasis to single lympn node, 2cm or less in size N2- Metastasis to single lymph node 2-5 cm in size, or multiple lymph nodes, none greater than 5 cm N3- Metastasis to a single lymph node >5cm in size M0- No distant metastasis M1- Distant metastasis T1,N0,M0 T2a,N0,M0 T2b,N0,M0 T3a,N0,M0 T3b,N0,M0 T4a,N0,M0 T4b,N0,M0 Any T,N1,M0 ...

Investigation of genetic polymorphisms and smoking in a bladder cancer case–control study in Argentina Lee E. Moore a,1 , John K. Wiencke b , Michael N. Bates a , Shichun Zheng b , Omar A. Rey c , Allan H. Smith a, * a School of Public Health, Arsenic Health Effects Research Program, University of California, 140 Warren Hall, Berkeley, CA 94720-7360, USA b University of California San Francisco Cancer Center, San Francisco, CA, USA c Facultad de Medicina, Universidad Catolica de Córdoba, Córdoba, Argentina Received 13 January 2004; received in revised form 15 April 2004; accepted 16 April 2004 Abstract We investigated the role of glutathione S-transferase (GST) enzymes (M1, T1), methylenetetrahydrofolate (MTHFR) 677 and 1298, and the NAD(P)H:quinone oxidoreductase ...

Amicus – Printing, bladder cancer and C23 benefit Page 1 of 6 PRINTING, BLADDER CANCER AND C23 BENEFIT INTRODUCTION Bladder Cancer is described as Prescribed Disease C23, and as such is one that has been officially accepted as a special risk of certain specified occupations, or of exposure to specified substances. Most occupational Bladder Cancers have been linked to work in the manufacture of dyestuffs, in the rubber and cable industries and in the retort houses of gasworks producing coal gas. However, it is widely accepted that the incidence of Bladder Cancer may be raised in certain other industries, including the printing industry. This has been recognised by many articles on Bladder Cancer , but in particular by the Industrial Injuries Advisory Council in their 1983 report on Neoplasm of the Bladder , where they stated that: "There is some evidence that certain ...

FOR IMMEDIATE RELEASE August 2, 2005 Moore’s bill encourages bladder cancer screening for all firefighters in the state BOSTON – Legislation sponsored by Senator Richard T. Moore (D-Uxbridge) that establishes a bladder cancer screening program within the Department of Public Health (DPH) was given a favorable report by the Committee on Health Care Financing today. “This bill aims to encourage firefighters to get screened for bladder cancer every year,” said Senator Moore. “It is extremely important to detect bladder cancer early. The survival rate is much higher. In addition, with the data collected through this program, the state can educate and prevent bladder cancer to certain high risk groups.” Senate bill 1301 requires the commissioner of the DPH to establish, promote, and maintain a public information program regarding the incidence of bladder cancer in professional ...

Combined radiotherapy and chemotherapy in muscle invasive bladder cancer RANDOMISATION CHECKLIST HOSPITAL DETAILS Hospital__ Consultant in charge __Person randomising Pt __ Referring Urologist _ Referring Hospital __ Yes No HAS THE ELIGIBILITY CHECKLIST BEEN COMPLETED? Yes No WRITTEN CONSENT OBTAINED? And for biological studies? WHICH PATIENT INFORMATION SHEET WAS USED? 2a 2b 2c Histology no. _ Where are blocks held?__ Reporting consultant Pathologist?_ PATIENT DETAILS Patient’s name Patient’s Initials Gender Male Female Hospital No Date of Birth NHS No. (or Postcode) WHO performance status (0-2 Only) Version 2 23/05/03 Date treatment expected to start: Yes No Has the patient completed the Quality of Life (FACT-BL) Assessment? Has the Clinical Oncologist completed ...

Iran Daily July 31, 2005 4 Great View! FERESHTEH $ 2,300 180 sq.m., 3 bdrms, 2 svcs, parquet fl., balcony, s/p, f. furn., sauna, jacuzzi MR. HAMID A Modern Life! UPPER VALI-E ASR $ 1,550 140 sq.m., 3 bdrms, 3 svcs, nice yard, parquet fl., gym, s/p, f. furn., sauna, jacuzzi MISS SARA Sweet Home! FERESHTEH $ 1,700 130 sq.m., 2 bdrms, 2 svcs, marble floor, open kitchen, nicely furnished, good location & entrance MR. DAVID SHAHRAK-E GHARB Phase 5 $ 2,500 170 sq.m., 3 bdrms, 3 svcs, open kit., marble fl., first flat with green yard & s/p MISS BARAN The Best Decoration Style! MIRDAMAD $ 1,200 110 sq.m., 2 bdrms, 2 svcs, open kit., ...

BILL WOULD TEST ALL FIREFIGHTERS FOR BLADDER CANCER , CREATE TRACKING SYSTEM By Amy Lambiaso STATE HOUSE NEWS SERVICE amy.lambiaso@statehousenews.com STATE HOUSE, BOSTON, JULY 27, 2005 ..Firefighters in Massachusetts could soon have free access to a test that could save their lives. Key lawmakers on Wednesday endorsed a proposal to include bladder cancer screening procedures as part of a firefighter's annual physical, and establish a registry with the state Department of Public Health to track incidents of bladder cancer among firefighters. Lawmakers say the program and registry would cost the state roughly $630,000 annually. Rep. Patricia Walrath, a Stow Democrat who chairs the Health Care Financing Committee, said bladder cancer is seen as an "occupational hazard" for firefighters, given their high exposure to toxins and chemicals emitted by fires. Similar legislative action in ...

_ Correspondence: Jeffrey T. Quirk, Department of Biology and Health Services, 150 Cooper Science Hall, Edinboro University of Pennsylvania, Edinboro, PA 16444, U.S. Email: jtq@velocity.net Fax: + 814-732-2422 ABSTRACT: Although cigarette smoking is a principal risk factor for bladder cancer in both men and women, few studies have statistically evaluated whether gender modifies the effect of smoking on bladder cancer risk. We initiated the present case-control study at Roswell Park Cancer Institute in Buffalo, New York, U.S., to provide further data on this important issue. We observed similar risk estimates for men and women with comparable smoking exposures, but did not observe a statistically significant interaction between gender and lifetime smoking exposure. We conclude that cigarette smoking is a major risk factor for bladder cancer in both sexes, but that gender does not modify the effect of ...

MDACC Suspicion of Bladder Cancer Clinical presentation: Hematuria and/or persistent irritative symptoms (e.g., pain, frequency) Urinalysis Urine culture Treat infection Positive culture Negative for blood Negative culture Negative for blood Positive culture Positive for blood Continue ongoing care with primary care physician Cystoscopy positive? (v1.1;4/99;2/29/00) Negative (with or without hematuria) Positive No Refer to Bladder Cancer Practice Guideline Persistent irritative symptoms? Persistent irritative symptoms? Positive for blood? Treat infection Repeat urinalysis Yes Continue ongoing care with primary care physician No Yes Yes No Yes Repeat cystoscopy with random biopsy No ...

May 5, 2005 MZT Matritech, Inc. (AMEX) Henry McCusker 617.236.6396 hwm@scimitarequity.com Please read the important Disclosures Section At the end of this review A test that saves lives Matritech is using its patented nuclear matrix protein (NMP) technology to develop diagnostics for the detection of major cancers. MZT’s first two products, the NMP22® Test Kit and NMP22®BladderChek® Test, have been approved for both the monitoring and diagnosis of bladder cancer . The Journal of the American Medical Association (JAMA) recently published the results of a large, multi-site clinical trial reporting that the NMP22® BladderChek® test detected cases of life threatening bladder cancer not detected by cystoscopy. The authors also reported that when used together, the NMP22 BladderChek® test and cystoscopy detected 94% of ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Bladder Cancer and Exposure to Ionizing Radiation 1 Bladder Cancer and Exposure to Ionizing Radiation Summary: There is strong evidence that bladder cancer may be associated with exposure to ionizing radiation. This evidence includes studies of nuclear workers. This is consistent with the National Research Council’s finding that the bladder is sensitive to ionizing radiation. Bladder cancer is designated as a “specified” cancer under the Energy Employees Occupational Illness Compensation Program Act. Historically, incidence of bladder cancer has been high in both Los Alamos County and Rio Arriba County. Mortality has been very low in Los Alamos County and moderate in Rio Arriba County. Incidence means new cases of cancer , while mortality means ...

Preliminary Analysis of Area-Level Drinking Water Arsenic and Bladder Cancer Incidence Rates in New Mexico, 1988-2002 Second Annual National Environmental Public Health Tracking Conference Atlanta, April 2005 Len Flowers M.S ., New Mexico Department of Health (NMDOH) Will Athas Ph.D ., University of New Mexico, Department of Family & Community Medicine Orrin Myers Ph.D ., University of New Mexico, Division of Epidemiology & Biostatistics Shirley Baros B.S ., University of New Mexico, Earth Data Analysis Center (EDAC) Funded by CDC Cooperative Agreement U50/CCU623291-02 Page 2 OVERVIEW New Mexico Drinking Water Arsenic and Cancer Incidence Linkage Demonstration Project Study Design: Ecologic, aggregate data linkage Geographic Level: Census tract (2000 US Census, N=456) Time Frame : 1988-2002 Health ...

Tracing Methods for Obtaining Residential Street Addresses for Non-Street Mailing Addresses in State Cancer Registry Records Second Annual National Environmental Public Health Tracking Conference Atlanta, April 2005 Will Athas Ph.D. University of New Mexico Department of Family & Community Medicine Barbara Toth Ph.D. / Len Flowers M.S. New Mexico Department of Health Funded by CDC Cooperative Agreement U50/CCU522441-02-3 Page 2 PURPOSE OF CASE ADDRESS TRACING STUDY Objective To explore methods for assigning a street address at diagnosis for cancer registry records originally containing a non-street mailing address, such as a PO box or rural route number. Rationale The quality of geospatial information in health datasets will influence the level of geographic analysis at which environmental public health tracking ...

Dr Peter Oehr is Professor of Nuclear Medicine at the University of Bonn, Germany. He is an independent expert for the German Federal Institute for Drugs and Medical Devices (BfArM) and is the Editor of the book PET and PET-CT in Oncology (Springer, 2004). From 1975 to 1979 he worked in the surgical clinic at Bonn University, working on transplantation, immunology and experimental surgery and was leader of the experimental and clinical laboratories in the clinic of nuclear medicine at the same university. He was the private instructor for experimental nuclear medicine from 1988 to the year 2000, also at the University of Bonn. Dr Oehr was a visiting lecturer at the University of Dusseldorf, lecturing in laser medicine. He has been the Associate Professor in Clinical Biochemistry at the University of Vilnius, Lithuania and Consultant in Biotechnology ...

Journal of the Egyptian Nat. Cancer Inst., Vol. 16, No. 3, September: 137-144, 2004 Predictors of Outcome after Radical Cystectomy for Bladder Cancer in Saudi Patients; Single Institution Experience ALAA A. MOKHTAR, M.D.*; MEDHAT M. EL-SEBAIE, M.D.** and NASER ELKUM, Ph.D.*** The Departments of Urology*, Oncology** and Biostatistics, Epidemiology & Scientific Computing***, King Faisal Specialist Hospital and Research Centre, Riyadh, KSA. ABSTRACT Aim of the Study: To evaluate different prognostic factors that may affect disease-specific survival in patients with bladder cancer following radical cystectomy. Methods: Between July 1975 and December 2000, 229 patients underwent radical cystectomy and urinary diversion for bladder cancer in King Faisal Specialist Hospital and Research Center (KFSH & RC), Riyadh, Saudi Arabia. 175 patients had available ...

A fact sheet from the Greater Bay Area Cancer Registry Urinary bladder cancer in the Greater Bay Area 1988-2002 Spring 2005 Urinary bladder cancer is the fourth most common cancer in non-Hispanic white males, comprising 7% of all invasive cancers diagnosed in the Greater Bay Area. In 2002, approxi- mately 1,100 cases were diagnosed and 241 deaths were due to bladder cancer in the Greater Bay Area. The greatest risk factor is smoking, with smokers twice as likely to be diagnosed with bladder cancer than nonsmokers. Figure 1. Age-adjusted incidence rates forurinary bladdercancer by sex and yearof diagnosis, GreaterBay Area, 1988-2002 Figure 2. Age-adjusted incidence rates for urinary blad- der cancer by sex and race/ethnicity, Greater Bay Area, 1988-2002 0 5 10 15 20 25 30 35 40 45 1988 1989 ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health July, 2001 Bladder Cancer The American Cancer Society estimates that bladder cancer will affect 87,500 people in the U.S. in 2001, accounting for 6% of all cancers diagnosed in the United States among men and 2% among women (ACS, 2001). In Massachusetts, the 1997 age-adjusted incidence rate of this cancer was 14.1 per 100,000 residents (MCR, 2000). Males are three times more likely to develop bladder cancer than females and whites are two times more likely to develop this disease than blacks. The risk of bladder cancer increases with age and the mean age at diagnosis is 68-69 years (ACS, 2000). The greatest risk factor for bladder cancer is cigarette smoking. Smokers are more than twice as likely to develop ...

Patient Description The patient is a 79-year-old male who presents with significant urinary frequency, urgency, and moderate dysuria of about six months’ duration. He had previously received a two-week course of a fluoroquinolone antibiotic from his primary care physician without clear improvement. He denies fever, chills, flank pain, or gross hematuria. He admits to a moderate decrease in his urinary force of stream, which has remained unchanged over the past year. His medical history is remarkable for two prior diagnoses of myocardial infarction, hypertension, chronic obstructive pulmonary disease, osteoarthritis, and a cerebral vascular accident with minimal motor deficit and mild memory loss. He was treated for tuberculosis 20 years ago. He has no current angina. Medications include atenolol, hydrochlorothiazide, and low-dose ...

Press Release FOR IMMEDIATE RELEASE Contacts: Dr. K. Wayne Marshall, President & CEO Bruno Maruzzo, Corporate Development 416-650-0060 x234 416-650-0060 x237 wmarshall@chondrogene.com bmaruzzo@chondrogene.com BLOOD-BASED BIOMARKERS USED TO DETECT BLADDER CANCER – First Published Application of the Sentinel Principle in Cancer – TORONTO, CANADA (May 17, 2005): ChondroGene Limited (TSX Venture: CDG) announced today that the results from a bladder cancer clinical study were presented in a poster entitled “ Gene Expression Profiling in Blood Cells Reveals Novel Biomarkers of Human Urinary Bladder Cancer ” at the American Society of Clinical Oncology (ASCO) meeting on May 16th. The study was conducted with researchers from the New York University School of Medicine and Memorial Sloan-Kettering Cancer Center in collaboration with ChondroGene ...

Modelling the recurrence of bladder cancer Gregorio Rubio 1 , Cristina Santamaria 1 , Belen Garcia 1 , and Jose Luis Pontones 2 1 Matematica multidisciplinar Universidad Politecnica Valencia (Spain) (e-mail: crisanna@imm.upv.es, magarmo5@imm.upv.es, grubio@imm.upv.es) 2 Hospital Universitario La Fe Valencia (Spain) (e-mail: pontones jos@gva.es) Abstract. The aim of this paper is to evaluate the risk of tumor recurrence of bladder cancer after surgical operation (TUR: Trans-urethral Resection). The prog- nostic significance of some clinical features in 454 patients with primary superficial bladder carcinoma is studied. The modelling procedure is featured within interval censored and right censored framework. Keywords: bladder carcinoma, prognostic factors, recurrence, interval–censored survival ...